Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 2
2020 4
2021 4
2022 8
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, Toyoshima A, Nagata K, Haberkorn U, Kratochwil C, Shinohara A, Hatazawa J, Giesel F. Liu Y, et al. Among authors: kaneda nakashima k. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):871-880. doi: 10.1007/s00259-021-05554-2. Epub 2021 Sep 18. Eur J Nucl Med Mol Imaging. 2022. PMID: 34537893 Free PMC article.
Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models.
Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, Toyoshima A, Nagata K, Shimosegawa E, Haberkorn U, Kratochwil C, Shinohara A, Giesel F, Hatazawa J. Watabe T, et al. Among authors: kaneda nakashima k. J Nucl Med. 2020 Apr;61(4):563-569. doi: 10.2967/jnumed.119.233122. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586001 Free PMC article.
Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine.
Aso A, Nabetani H, Matsuura Y, Kadonaga Y, Shirakami Y, Watabe T, Yoshiya T, Mochizuki M, Ooe K, Kawakami A, Jinno N, Toyoshima A, Haba H, Wang Y, Cardinale J, Giesel FL, Shimoyama A, Kaneda-Nakashima K, Fukase K. Aso A, et al. Among authors: kaneda nakashima k. Int J Mol Sci. 2023 May 12;24(10):8701. doi: 10.3390/ijms24108701. Int J Mol Sci. 2023. PMID: 37240044 Free PMC article.
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.
Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, Haba H, Toyoshima A, Cardinale J, Giesel FL, Tomiyama N, Fukase K. Watabe T, et al. Among authors: kaneda nakashima k. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):849-858. doi: 10.1007/s00259-022-06016-z. Epub 2022 Nov 8. Eur J Nucl Med Mol Imaging. 2023. PMID: 36344651 Free PMC article.
Role of Mel1/Prdm16 in bone differentiation and morphology.
Kaneda-Nakashima K, Igawa K, Suwanruengsri M, Naoyuki F, Ichikawa T, Funamoto T, Kurogi S, Sekimoto T, Yamashita Y, Chosa E, Yamaguchi R, Morishita K. Kaneda-Nakashima K, et al. Exp Cell Res. 2022 Jan 15;410(2):112969. doi: 10.1016/j.yexcr.2021.112969. Epub 2021 Dec 7. Exp Cell Res. 2022. PMID: 34883111
α-Emitting cancer therapy using 211 At-AAMT targeting LAT1.
Kaneda-Nakashima K, Zhang Z, Manabe Y, Shimoyama A, Kabayama K, Watabe T, Kanai Y, Ooe K, Toyoshima A, Shirakami Y, Yoshimura T, Fukuda M, Hatazawa J, Nakano T, Fukase K, Shinohara A. Kaneda-Nakashima K, et al. Cancer Sci. 2021 Mar;112(3):1132-1140. doi: 10.1111/cas.14761. Epub 2021 Jan 22. Cancer Sci. 2021. PMID: 33277750 Free PMC article.
21 results